Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study

Fig. 3

Potential biomarkers associated with efficacy. The responses at different time points when the cytokines were measured were showed in the upper panel. Levels of serum cytokines at different treatment cycles from 8 patients were analyzed against the corresponding response status. Among these cytokines, Eotaxin and MCP-1 levels showed a positive relationship with PR status, while TGF-alpha and VEGF levels correlated with PD (iuPD/icPD) status. Unpaired T- test was performed to analyze the difference of serum cytokines between PR and PD groups. P < 0.05 *, P < 0.01 **, P < 0.001 ***

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us